Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

Why Earnings Season Could Be Great for Ascendis Pharma (ASND)

Why Earnings Season Could Be Great for Ascendis Pharma (ASND)

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Biotech With 520% Sales Growth Nears Next Buy Point

Two Health Care Stocks Outperform S&P 500, Offer Entries

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

Ascendis Pharma A/S (ASND) Rose on Positive Trial Results

Buy Rating Affirmed for Ascendis Pharma Amid Favorable Market Dynamics and Strong TransCon PTH Outlook

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), Conmed (CNMD) and Ascendis Pharma (ASND)

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4

Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?